Subcutaneous · GLP-1 / glucagon dual
PB-718
2 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
2
Active
0
Recruiting
0
Completed
2
Sites
2
Countries
2
Endpoints
14
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 1/2
1
Trials by status
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
11
Weight & body composition
2
Glycemic / diabetes
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT05021666A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study | PB-718 Healthy volunteers, Obesity / overweight | BMI 20-30 | Ph 1 | Completed | 1 | May 2022 | — | |
| NCT06147544A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects. | PB-718 Obesity / overweight | BMI ≥28 | Ph 1/2 | Completed | 1 | Apr 2024 | — |